For nearly fifty years, acute myeloid leukemia stood as one of cancer medicine's most stubborn problems.

The treatment landscape barely moved. Intensive chemotherapy, introduced in the 1970s, remained the backbone of care. For some patients, it could be curative. For many others, especially older or frailer patients, it was too toxic to tolerate. And for decades, when chemotherapy was not an option or stopped working, there were very few meaningful alternatives.

This is the gap Andrew Kent has spent his career moving toward.

He is an MD-PhD, hematologist-oncologist, transplant physician, and clinical researcher. His work sits in the difficult space between what is biologically possible and what is clinically available. In a single week, that can mean caring for a patient facing a new diagnosis, thinking through an early-phase trial, and studying sequencing data to understand why one person responded to therapy while another did not.

That position matters because AML has never been an easy disease to solve.

The cancer that resists simple answers

To understand why AML held out so long, it helps to sit with a strange fact about the disease. Over the past fifteen years, immunotherapy has changed the way many cancers are treated. In several solid tumors, checkpoint inhibitors helped the immune system recognize cancer as foreign and attack it more effectively.

AML did not follow the same script. The reason lies in where the disease comes from.

AML arises from blood-forming cells, the same broad system that gives rise to immune cells. That makes the disease unusually difficult to target. The immune system is not simply being asked to attack an outside enemy. In a way, it is being asked to confront something that comes from within its own lineage.

As Kent puts it, "You have to get the healthy myeloid cells to attack their neighbors, if you will."

That is the paradox at the center of AML immunotherapy.

The target and the weapon are too closely related. Many markers found on leukemic cells are also present on normal hematopoietic stem cells. A therapy may recognize the leukemia, but it may also damage healthy bone marrow. In some cases, that trade-off can mean wiping out the marrow and requiring a stem cell transplant afterward.

So the challenge sounds deceptively simple: find targets present on leukemic cells but absent from normal blood-forming cells.

In practice, that has been one of the hardest problems in the field.

AML immunotherapy, Kent says, can feel like "trying to use a dysfunctional immune system to treat itself."

Where curiosity became urgency

He did not come to this problem all at once. It accumulated.

Kent did not arrive at AML research through one dramatic turning point. His career path was more gradual, and perhaps more telling.

It began with scientific curiosity. He was drawn to cancer immunology, the bone marrow microenvironment, and the question of how the immune system distinguishes abnormal cells from normal ones. How does it identify a mutated cell? How does it learn what to attack? And how can that recognition be directed toward a specific target?

"I came at it from an immunologist's perspective," he says, "just trying to understand how the immune system can differentiate mutated cells from normal cells, how you get it to point at a specific target."

But the clinic changed the stakes of the question.

The more time he spent with patients with malignant hematologic diseases, the harder it became to separate scientific interest from clinical need. AML was not only a fascinating immunologic problem. It was a disease where patients were still waiting for better answers.

Some could not tolerate intensive chemotherapy. Some relapsed after it. Some reached the point where standard options had been exhausted. For those patients, the limits of the field were not theoretical.

They were conversations happening in the clinic.

"The malignant hematology really merged my interest in the immunology behind all of our therapies," he says, "but also this huge patient need for new therapies in the space."

That merger has shaped the rest of his work: a career built around making biology actionable.

A field finally in motion

AML care is now changing in ways that would have seemed unlikely a generation ago.

The question is no longer simply whether a patient can tolerate chemotherapy. It is increasingly about age, fitness, disease genetics, treatment goals, response patterns, and what the leukemia's molecular profile reveals.

One major shift has been the use of venetoclax and azacitidine for older or less fit patients. These were patients who, in earlier eras, may have had no tolerable treatment option at all. As the combination began producing meaningful responses, the field started asking a new question: if a less intensive regimen can work, should it remain limited to older patients?

That question has pushed venetoclax-based approaches into broader clinical use, including in some younger cohorts. But the progress has also created a new challenge. Not every patient responds. And in AML, knowing early that a therapy is unlikely to work can be critical.

This is where genetics has begun to reshape treatment decisions.

A patient with a FLT3 mutation may receive a FLT3 inhibitor with intensive chemotherapy, if they are fit enough. A patient with favorable-risk core-binding-factor AML may still receive chemotherapy because, in that setting, chemotherapy can be curative and may help avoid transplant. Other patients may be considered for venetoclax-based regimens, menin inhibitor combinations, targeted therapies, or clinical trials.

"It's a dramatic shift to a lot more venetoclax in a lot more cohorts," Kent says, "very focused use of chemotherapy when it can be curative, and then targeted therapy additions if possible, based on the genetics."

That is the new AML landscape: more options, more stratification, and more need to understand which patient should receive which therapy, and when.

The field is no longer only asking, "What is the next target?"

It is asking harder questions. Who benefits from this target? Which combinations deepen response? Which sequence of therapy gives the best chance of durable benefit? Why does one patient respond while another does not? And when resistance appears, what biology explains it?

The loop between clinic and discovery

For Kent, the clinic and the lab are not two separate worlds but two ends of one loop.

Early-phase trials often begin where the need is most urgent: in patients with relapsed or refractory disease, where standard therapies have already failed. These trials are not yet ready to replace first-line treatment. But for patients who have run out of options, having a trial available can matter deeply.

"We love to have trials open and available," he says, "so that we can offer something instead of just supportive care, which is a very hard thing to say as a provider."

The loop also runs in the opposite direction.

Every patient treated with a newer therapy adds to the field's understanding of response and resistance. A response becomes evidence. A non-response becomes a question. A relapse becomes a clue. A stored sample becomes a way to look back and ask what the disease was doing at the molecular level.

At his institution, patient samples are studied alongside treatment outcomes. These are not clean experimental systems. They are real patients, with real disease histories, receiving real therapies. By comparing those outcomes, researchers can identify patterns of sensitivity and resistance, generate hypotheses, test combinations preclinically, and design the next trial.

"It's a constant, cyclic process," Kent says.

That cycle is where modern translational research increasingly lives: not only at the bench, and not only in the clinic, but in the movement between them.

Why data is becoming part of the treatment story

As the picture grows more molecular, the bottleneck shifts, from generating data to making sense of it fast enough to act.

As AML care becomes more molecularly detailed, the field is generating more information than ever before: clinical records, sequencing reports, treatment histories, response data, relapse patterns, outcomes, and trial data.

The challenge is no longer only producing data. It is using it quickly enough to matter.

That is where Kent sees a practical role for artificial intelligence.

The clearest value today is reducing the friction of working with large clinical datasets. Manually extracting and analyzing information from medical records is slow. As datasets grow, that approach becomes harder to sustain.

"The larger our clinical data sets get," he says, "the more cumbersome it is to manually sift through and analyze."

AI tools could help accelerate that work: extracting information from electronic medical records, supporting analytics, and helping researchers move faster from observation to hypothesis.

There is also a clinical knowledge gap to consider. A community oncologist may see only a few AML cases a year. A specialist center may be more familiar with emerging regimens, mutation-specific decisions, and trial options. With the right tools, AI could help synthesize evidence and support more complete treatment planning.

The longer-term possibility is even broader: connecting public biomedical knowledge with institutional clinical datasets to surface questions researchers may not have thought to ask.

The framing, however, is careful. AI is not replacing discovery. It is shortening the distance between steps.

"I'd say it's just accelerating every step of our discovery pathway."

The question that keeps the work grounded

AML is now surrounded by complexity: sequencing panels, targeted therapies, immune strategies, trial design, transplant decisions, clinical datasets, and AI-enabled analysis.

But the principle guiding the work is much simpler.

"It's so easy to get caught up in all the medical knowledge and research and trials and everything," Kent says. "It's easy to lose sight of the ultimate goal, which is: we want to help treat people better. It's very simple."

That question keeps the work oriented.

Will this help treat people better?

For a disease that waited nearly fifty years for meaningful change, that is not a sentimental question. It is the point of the work.

It is what connects a patient in the clinic to a sample in the lab. It is what connects sequencing data to a treatment decision. It is what turns a failed response into the next hypothesis. And it is what keeps the next trial connected to the gap it is trying to close.

Written by Arushi Batra, PhD, based on a conversation with Dr. Andrew Kent as part of Elucidata's leadership series spotlighting voices in drug and target discovery.

‍